Articles published by Newron Pharmaceuticals S.p.A.

EA Pharma, a subsidiary of Eisai, Announces the Initiation of its Phase III Clinical Trial with Evenamide, a Novel Treatment for Schizophrenia, in Japan

January 07, 2026

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

January 06, 2026

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron to Host Investor and Partnering Meetings During the J.P. Morgan Healthcare Conference Week

December 22, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Announces the US Initiation of Its ENIGMA-TRS 2 Phase III Global Clinical Study With Evenamide as an Add-On Therapy for Patients With Treatment-Resistant Schizophrenia (TRS)

December 08, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron to Present New Analyses From and Updates on its Clinical Program Evaluating Evenamide as an Add-on Treatment for Schizophrenia at the 38th European College of Neuropsychopharmacology (ECNP) Congress 2025

October 02, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron presents H1 2025 results and provides business update

September 16, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron to present data and updates on its clinical program evaluating evenamide as an add-on treatment for schizophrenia at the 2025 World Congress of Biological Psychiatry (WCBP)

September 05, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Begins Enrollment in Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-Resistant Schizophrenia (TRS)

August 12, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Notes the Publication of New Preclinical Research Suggesting Evenamide Ameliorates Schizophrenia-Related Dysfunction

August 11, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Announces Approval for Pivotal Phase III ENIGMA-TRS Program With Evenamide as Add-on Therapy in Patients With Treatment-resistant Schizophrenia (TRS)

May 12, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Presents 2024 Financial Results and Provides 2025 Outlook

April 01, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron proposes renowned biopharma company founder and entrepreneur Dr. Chris Martin for election as Independent Chairman

March 24, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Pharmaceuticals to Participate in a Fireside Chat at the 37th Annual ROTH Conference

March 11, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron and Myung In Pharm Announce License Agreement for evenamide in South Korea

January 09, 2025

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron and EA Pharma (A Subsidiary of Eisai Co., Ltd.) Announce License Agreement for Evenamide in Japan and Other Asian Territories

December 13, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron presents H1 2024 results and provides business update

September 19, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Pharmaceuticals Reports on Its 2024 Investor Day in New York City

June 25, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Pharmaceuticals 2024 Investor Day on June 25, 2024, in New York City

June 18, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Pharmaceuticals Will Host Its 2024 Investor Day on June 25 in New York City

June 05, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Reports Compelling Additional Data Documenting the Efficacy of Evenamide in Pivotal Study 008A in Poorly Responding Schizophrenia Patients

May 13, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Announces Positive Top-line Results From Potentially Pivotal Phase II/III Study 008A With Evenamide in Schizophrenia Patients

April 30, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)

April 08, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Presents 2023 Financial Results and Provides 2024 Outlook

March 19, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement

March 15, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Reports Exceptional One-year Results of Study 014/15 With Evenamide in Treatment-resistant Schizophrenia (TRS)

January 04, 2024

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Completes Enrollment of Schizophrenia Patients in Potentially Pivotal Study 008A With Evenamide

December 29, 2023

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron TRS Study 6 Months’ Results: Evenamide Substantially Improves Patients to an Extent That They No Longer Meet Protocol Entry Criteria

October 09, 2023

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron to Present Three Posters on Its Clinical Program Evaluating Evenamide in the Treatment of Schizophrenia at the 36th European College of Neuropsychopharmacology Congress

October 04, 2023

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Appoints Margarita Chavez as Board Advisor

October 02, 2023

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Newron Announces H1 2023 Results and Provides R&D Update

August 04, 2023

From Newron Pharmaceuticals S.p.A.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.